Neuroendocrine Cancer
If it’s your first time on this website, please read the disclaimer section.
Jul 06 – Jul 13, 2026
OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancer.
COMMUN MED-LONDON · Q1 JOURNAL - RANK #33/195
This prospective clinical trial evaluated the safety and immunological effects of EO2401, an off-the-shelf OncoMimic peptide-based immunotherapy combined with nivolumab in patients with advanced adrenal tumors. Using T cell receptor repertoire sequencing, investigators profiled TCR architecture in patients with adrenocortical carcinoma (ACC), identifying a restricted T cell richness in their peripheral blood. Results showed that EO2401 diversified pre-existing T cell clusters but did not induce highly shared TCR clones across patients. The combined therapy broadens and activates public T cell responses, suggesting potential for improved cancer immunotherapy outcomes in ACC.
10.1038/s43856-026-01755-8
Jun 29 – Jul 06, 2026
Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.
BRIT J CANCER · Q1 JOURNAL - RANK #47/326
This Phase IIa prospective, single-arm trial assessed foslinanib (CVM-1118), an oral anti–vasculogenic mimicry agent, in advanced well‑differentiated NETs refractory/intolerant to prior therapy. Patients (N=43; 35 efficacy‑evaluable) with grade 1–2 lung, gastrointestinal, or pancreatic NETs received CVM‑1118 200–300 mg twice daily in 28‑day cycles; primary endpoint was PFS, with ORR, DCR, OS, and safety secondary. Median PFS was 10.5 months (95% CI 5.6–22.3), ORR 3%, DCR 77%, and median OS not reached (95% CI 23.8–NR); in the full analysis set (N=43), median PFS was 8.4 months, and among those with prior everolimus, sunitinib, or PRRT (N=22), median PFS was 8.3 months. Treatment‑related AEs occurred in 44%, mostly grade 1–2, with no serious events, supporting favorable efficacy and tolerability.
10.1038/s41416-026-03515-w
Jun 22 – Jun 29, 2026
Phase II study of 1st-line durvalumab and platinum-etoposide in advanced large-cell neuroendocrine lung carcinoma (aLCNEC).
CANCER IMMUNOL IMMUN · Q1 JOURNAL - RANK #68/326
This phase II single-arm clinical trial investigated the safety and efficacy of first-line durvalumab combined with platinum-etoposide in patients with advanced large-cell neuroendocrine carcinoma (aLCNEC). The primary endpoint was 12-month progression-free survival (PFS), with secondary endpoints including overall response rate (ORR), overall survival (OS), and safety. Out of 12 enrolled patients (median age 68; 92% smokers; 92% with disease progression), the 12-month PFS was 25.0% (95% CI 6.0-50.5%), exceeding the null hypothesis threshold, while the 12-month OS was 58.3% (95% CI 27.0-80.1%). The treatment showed manageable toxicity with efficacy consistent with the study design, despite early study closure due to low enrollment.
10.1007/s00262-026-04464-2
Jun 15 – Jun 22, 2026
The first-in-human ENCIT01 trial comparing second- versus third-generation L1CAM-specific CAR T cells in patients with primary refractory or relapsed neuroblastoma.
CLIN CANCER RES · Q1 JOURNAL - RANK #29/326TOP-TIER
ENCIT-01 was a first-in-human, prospective interventional trial comparing three L1CAM-targeted CAR T-cell constructs (Arm A: 2GS short spacer 4-1BB; Arm B: 3GS short spacer 4-1BB+CD28; Arm C: 2GL long spacer 4-1BB) in children with relapsed/refractory neuroblastoma. Thirty-six patients were enrolled, 22 treated (A n=11, B n=8, C n=3), and 34/36 products were successfully manufactured. Grade ≥2 toxicities included cytokine release syndrome, skin rash, and hyponatremia; hyponatremia was dose-limiting in 3 patients (DL5 Arm A, DL3 Arm B, DL2 Arm C), with toxicity patterns emerging at lower dose levels in Arms B and C. No objective responses were observed; correlative analyses detected CAR T cells in tumor and skin and macrophage infiltration, leading to the conclusion that L1CAM may be an unsuitable target and further engineering is needed to improve safety and efficacy.
10.1158/1078-0432.CCR-26-0009
Bintrafusp alfa for patients with recurrent or metastatic olfactory neuroblastoma.
CANCER IMMUNOL IMMUN · Q1 JOURNAL - RANK #68/326
This prospective, single-arm clinical trial (NCT05012098) investigated bintrafusp alfa, a bifunctional TGF-β trap/anti-PD-L1 fusion protein, in 11 patients with recurrent or metastatic olfactory neuroblastoma who received 1200 mg intravenously every two weeks. The primary endpoint was overall response rate; secondary endpoints included safety, progression-free survival (PFS) and overall survival (OS). No objective responses were observed, but 4/8 evaluable immunotherapy-naïve patients (50 %) and 1/2 pre-treated patients achieved stable disease; median PFS was 3.7 months (cohort 1) and 3 months (cohort 2), while median OS was not reached and 6.8 months, respectively. Grade 3–4 treatment-related adverse events occurred in three patients, indicating a manageable safety profile despite absence of confirmed responses.
10.1007/s00262-026-04462-4
Jun 01 – Jun 08, 2026
SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This open-label, phase 1 clinical trial assessed the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ABBV-706, a SEZ6-targeting antibody-drug conjugate, in 288 patients with advanced solid tumors, with a focus on 124 relapsed/refractory (R/R) small cell lung cancer (SCLC) patients. ABBV-706 was administered intravenously every 3 weeks, with safety outcomes highlighting anemia (61%) and fatigue (38%) as the most common treatment-related adverse events in the monotherapy cohort, and grade 3 or higher adverse events in 61% of R/R SCLC patients. Efficacy data showed an objective response rate of 52% in R/R SCLC, with comparable ORRs (56% and 59%) between 1.8 mg/kg and 2.5 mg/kg doses and median overall survival of 12.4 months at 1.8 mg/kg. The study concluded 1.8 mg/kg as the recommended phase 2 dose based on safety and efficacy.
10.1038/s41591-026-04452-0